China nationwide screening and registry of primary aldosteronism in hypertensive patients.

In the framework of the China Hypertension Control Initiatives, the China Primary Aldosteronism Prospective Study was designed as a nationwide multicenter programme for the screening and registry of primary aldosteronism in hypertensive patients. The primary objective was to establish technological platforms, team and expertise for the screening, diagnosis and treatment of primary aldosteronism in cardiology outpatient clinics. From 18 July 2018 to 31 May 2020, 1329 patients from 14 cities had been screened. 348 (26.2%) patients had a plasma aldosterone-to-renin ratio of ≥40 (pg/ml)/(pg/ml) and enroled in the registry. 175 (50.3%) patients had confirmatory testing, of whom 163 (93.1%) had a confirmed diagnosis of primary aldosteronism.